<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940506-0-00039</title>
	</head>
	<body>
		<main>
			<p><!-- PJG ITAG l=10 g=1 f=2 --> EFFECTIVE DATE:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> May 6, 1994.  <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> <!-- PJG STAG 4700 -->  <!-- PJG ITAG l=94 g=1 f=4 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=69 g=1 f=4 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=50 g=1 f=4 -->   <USDEPT>DEPARTMENT OF HEALTH AND HUMAN SERVICES</USDEPT>  <!-- PJG /ITAG -->  <!-- PJG ITAG l=18 g=1 f=4 -->  <USBUREAU>Food and Drug Administration</USBUREAU> <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=52 g=1 f=4 -->  <CFRNO>21 CFR Parts 606 and 660</CFRNO> <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=41 g=1 f=4 -->  <RINDOCK>[Docket No. 92N&hyph;0497]</RINDOCK> <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=55 g=1 f=4 --> Biological Products; Blood Specificity Designators; Technical Amendments <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <AGENCY> <!-- PJG ITAG l=10 g=1 f=2 --> AGENCY:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Food and Drug Administration, HHS. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </AGENCY> <ACTION> <!-- PJG ITAG l=10 g=1 f=2 --> ACTION:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Final rule; technical amendments. <!-- PJG /ITAG -->  <!-- PJG ITAG l=59 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </ACTION> <SUMMARY> <!-- PJG ITAG l=10 g=1 f=2 --> SUMMARY:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> The Food and Drug Administration (FDA) is amending the biologics regulations to correct certain omissions from the designators for blood specificities and make other minor, technical amendments. This action is being taken to clarify and improve the accuracy of the regulations. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </SUMMARY> <DATE> <!-- PJG ITAG l=10 g=1 f=2 --> EFFECTIVE DATE:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> May 6, 1994.  <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> </DATE> <FURTHER> <!-- PJG ITAG l=10 g=1 f=2 --> FOR FURTHER INFORMATION CONTACT:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Paula S. McKeever, Center for Biologics Evaluation and Research (HFM&hyph;635), Food and Drug Administration, 1401 Rockville Pike, suite 200N, Rockville, MD 20852, 301&hyph;594&hyph;3074. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </FURTHER> <SUPPLEM> <!-- PJG ITAG l=10 g=1 f=2 --> SUPPLEMENTARY INFORMATION:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> FDA is correcting certain errors that have been incorporated into the biologics regulations in parts 606 and 660 (21 CFR parts 606 and 660). The errors in the regulations are as follows: <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 1. In the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=4 --> Federal Register <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  of April 19, 1988 (53 FR 12760), FDA changed the name of ``Blood Grouping Serum'' to ``Blood Grouping Reagent'' to more accurately describe the product's derivation and intended use. However, in &sect;&sect; 606.65(c) and 606.121(c)(12)(i), (c)(12)(ii), and (c)(12)(iii), the name change was inadvertently omitted. The agency is correcting these errors. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 2. In the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=4 --> Federal Register <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  of February 11, 1985 (50 FR 5574), FDA changed the name of ``Anti-Human Serum'' to ``Anti-Human Globulin'' to reflect that this product may be produced from immunoglobulin-secreting cell lines as well as from serum. However, in  606.65(c), the name change was inadvertently omitted. The agency is correcting this error.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 3. Further, in &sect;660.28(a), the agency is revising the blood group antibody designations ``Anti-c,'' and ``Anti-k,'' as ``Anti-,'' and ``Anti-,''respectively. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Publication of this document constitutes final action on these changes under the Administrative Procedure Act (5 U.S.C. 553). Notice and public procedure and delayed effective date on this final rule are unnecessary because the changes are editorial in nature and nonsubstantive (5 U.S.C. 553(b) and (d)).  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=84 g=1 f=1 --> List of Subjects <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=83 g=1 f=1 --> 21 CFR Part 606 <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Blood, Labeling, Laboratories, Reporting and recordkeeping requirements. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=83 g=1 f=1 --> 21 CFR Part 660 <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Biologics, Labeling, Reporting and recordkeeping requirements. <!-- PJG 0012 frnewline --> Therefore, under the Federal Food, Drug, and Cosmetic Act, the Public Health Service Act, and under authority delegated to the Commissioner of Food and Drugs, 21 CFR parts 606 and 660 are amended as follows: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=52 g=1 f=1 --> PART 606_CURRENT GOOD MANUFACTURING PRACTICE FOR BLOOD AND BLOOD COMPONENTS <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 1. The authority citation for 21 CFR part 606 continues to read as follows: <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=4 --> Authority:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 --> Secs. 201, 301, 501, 502, 505, 510, 520, 701, 704 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321, 331, 351, 352, 355, 360, 360j, 371, 374); secs. 215, 351, 353, 361 of the Public Health Service Act (42 U.S.C. 216, 262, 263a, 264). <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=80 g=1 f=1 --> &sect;606.65  <!-- PJG /ITAG -->  <!-- PJG ITAG l=89 g=1 f=1 --> [Amended] <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 --> 2. Section 606.65  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Supplies and reagents <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  is amended in the table in paragraph (c), under the heading ``Reagent or solution'' by removing the words ``Anti-human serum'' and adding in their place the words ``Anti-human globulin'', and by removing the words ``Blood grouping serums'' and adding in their place the words ``Blood grouping reagents''. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=80 g=1 f=1 --> &sect;606.121  <!-- PJG /ITAG -->  <!-- PJG ITAG l=89 g=1 f=1 --> [Amended] <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 --> 3. Section 606.121  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Container label <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  is amended in paragraphs (c)(12)(i), (c)(12)(ii), and (c)(12)(iii) by removing the word ``Serum'' wherever it appears, and by adding in its place the word ``Reagent''. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=52 g=1 f=1 --> PART 660_ADDITIONAL STANDARDS FOR DIAGNOSTIC SUBSTANCES FOR LABORATORY TESTS <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 4. The authority citation for 21 CFR part 660 continues to read as follows: <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=4 --> Authority:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 --> Secs. 201, 501, 502, 503, 505, 510, 701 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321, 351, 352, 353, 355, 360, 371); secs. 215, 351, 352, 353, 361 of the Public Health Service Act (42 U.S.C. 216, 262, 263, 263a, 264). <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=80 g=1 f=1 --> &sect;660.28  <!-- PJG /ITAG -->  <!-- PJG ITAG l=89 g=1 f=1 --> [Amended] <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0141 unknown --> 001 <!-- PJG ITAG l=11 g=1 f=1 --> 5. Section 660.28  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Labeling <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  is amended in the table in paragraph (a)(1), under the heading ``Blood grouping reagent'' by removing ``Anti-&cacute;'' and adding in its place ``Anti-''; in paragraph (a)(4), in the second sentence, by removing ``Anti-k'' the second time it appears and adding in its place ``Anti-''. <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 --> Dated: May 2, 1994. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SUPPLEM> <SIGNER> <!-- PJG ITAG l=06 g=1 f=1 -->  Michael R. Taylor, <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNER> <SIGNJOB> <!-- PJG ITAG l=04 g=1 f=1 -->  Deputy Commissioner for Policy. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNJOB> <FRFILING> <!-- PJG ITAG l=40 g=1 f=1 --> [FR Doc. 94&hyph;10997 Filed 5&hyph;5&hyph;94; 8:45 am] <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </FRFILING> <BILLING> <!-- PJG ITAG l=68 g=1 f=1 --> BILLING CODE 4160&hyph;01&hyph;F <!-- PJG /ITAG --> </BILLING>  <!-- PJG /STAG --></p>
		</main>
</body></html>
            